



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Herbert T. Nagasawa and Jonathan F. Cohen  
Serial No.: 10/750,005  
Filed: December 30, 2003  
Docket: 30452.2USU1  
Title: METHODS FOR REDUCING OXIDATIVE STRESS IN A CELL WITH A SULFHYDRYL  
PROTECTED GLUTATHIONE PRODRUG

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 14, 2006.

By: [Signature]  
Name: Richelle Ann Domingo

MAIL STOP AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Information Disclosure Statement (37 C.F.R. §1.97 (c))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 28-42
- ☒ Check in the amount of \$180.00 to cover the filing fee
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
(626)395-7801

By: [Signature]  
Name: Sarah B. Adriano  
Reg. No.: 34,470  
Initials: SBA  
Customer No.: 26,941




**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Hebert T. Nagasawa et al.      **Examiner:** T. S. Heard  
**Serial No.:** 10/750,005      **Group Art Unit:** 1654  
**Filed:** December 30, 2003      **Docket No.:** 30452.2USU1  
**Title:** METHODS FOR REDUCING OXIDATIVE STRESS IN A CELL WITH A SULFHYDRYL PROTECTED GLUTATHIONE PRODRUG

**CERTIFICATE UNDER 37 CFR §1.8:**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on March 14, 2006.

By:   
Richelle Ann Domingo

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**(37 C.F.R. § 1.97(c))**

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed herein as a supplement to Applicant's July 19, 2004 and February 28, 2005 Information Disclosure Statements which were submitted under 37 C.F.R. §§1.97(b)(3). In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 28-42 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- U.S. Patent No. 5,382,679, issued on January 17, 1995, Galzigna. (Exhibit 28)
- U.S. Patent No. 5,824,693, issued on October 20, 1998, Goldberg. (Exhibit 29)


- U.S. Patent No. 6,197,749, issued on March 6, 2001, Hamuro et al. (Exhibit 30)
- U.S. Patent No. 6,369,106, issued on April 9, 2002, Atlas et al. (Exhibit 31)
- U.S. Patent No. 6,586,404, issued on July 1, 2003, Demopolos et al. (Exhibit 32)
- European Patent application 0 494 405 published on July 15, 1992. (Exhibit 33)
- European Patent application 0 501 641 published on September 2, 1992. (Exhibit 34)
- European Patent application 0 572 110 published on December 1, 1993. (Exhibit 35)
- PCT Patent application WO 98/29375 published on July 9, 1998. (Exhibit 36)
- PCT Patent application WO 01/80832 published on November 1, 2001. (Exhibit 37)
- PCT Patent application WO 02/090314 published on November 14, 2002. (Exhibit 38)
- PCT Patent application WO 02/17962 published on March 7, 2002. (Exhibit 39)
- PCT Patent application WO 05/025570 published on March 24, 2005. (Exhibit 40)
- Purdie, J.W., "Gamma-Radiolysis of Cysteine-Cysteamine Disulfide in Aqueous Solution," *Canadian Journal of Chemistry*, 1971, 49:725-30. (Exhibit 41)
- Sato, Shigeru et al., "Identification of Thioether Intermediates in the Reductive Transformation of Gonyautoxins in Saxitoxins by Thiols," *Bioorganic & Medicinal Chemistry Letters*, 2000, 10:1787-9. (Exhibit 42)

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Applicants invite the Patent Office to request additional information if necessary. Pursuant to the provisions of M.P.E.P. § 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

A fee in the amount of \$180.00 is deemed necessary in connection with the filing of this Information Disclosure Statement. If any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano  
Registration No. 34,470  
SaraLynn Mandel  
Registration No. 31,853  
Mandel & Adriano  
55 S. Lake Avenue, Suite 710  
Pasadena, California 91101  
(626) 395-7801  
Customer No. 26,941

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	<b>Docket Number</b> 30452.2USU1	<b>Application Number</b> 10/750,005
	<b>Applicant</b> Herbert T. Nagasawa and Jonathan F. Cohen	
	<b>Filing Date</b> December 30, 2003	<b>Group Art Unit</b> 1654

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,382,679	January 17, 1995 (EXHIBIT 28)	Galzigna				
	5,824,693	October 20, 1998 (EXHIBIT 29)	Goldberg				
	6,197,749	March 6, 2001 (EXHIBIT 30)	Hamuro et al.				
	6,369,106	April 9, 2002 (EXHIBIT 31)	Atlas et al.				
	6,586,404	July 1, 2003 (EXHIBIT 32)	Demopolos et al.				
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 494 405	July 15, 1992 (EXHIBIT 33)	EP				
	EP 0 501 641	September 2, 1992 (EXHIBIT 34)	EP				
	EP 0 572 110	December 1, 1993 (EXHIBIT 35)	EP				
	WO 98/29375	July 9, 1998 (EXHIBIT 36)	US				
	WO 01/80832	November 1, 2001 (EXHIBIT 37)	US				
	WO 02/090314	November 14, 2002 (EXHIBIT 38)	US				
	WO 02/17962	March 7, 2002 (EXHIBIT 39)	US				
	WO 05/025570	March 24, 2005 (EXHIBIT 40)	US				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Purdie, J.W., "Gamma-Radiolysis of Cysteine-Cysteamine Disulfide in Aqueous Solution," <i>Canadian Journal of Chemistry</i> , 1971, 49:725-30. (Exhibit 41)					
		Sato, Shigeru et al., "Identification of Thioether Intermediates in the Reductive Transformation of Gonyautoxins in Saxitoxins by Thiols," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2000, 10:1787-9. (Exhibit 42)					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE